Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
06 10월 2023 - 5:30AM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, presented new
preclinical data supporting the potential benefit of ATH-1105 for
the treatment of amyotrophic lateral sclerosis (ALS) at the 22nd
Annual Northeast ALS Consortium (NEALS) Meeting, taking place
October 4-6, 2023, virtually and in-person in Clearwater, Florida.
ATH-1105 is an orally administered small molecule therapeutic
candidate designed to enhance the neurotrophic hepatocyte growth
factor (HGF) system.
“Our findings add to the growing body of evidence that ATH-1105
offers broad neuroprotective activity in preclinical models of ALS,
including the rescue of motor neurons from insults in vitro and
reduction in plasma neurofilament light (NfL), decreased pTDP-43
accumulation in nerves, and improvements in motor and nerve
function in vivo,” stated Kevin Church, Ph.D., Chief Scientific
Officer, Athira Pharma. “There is an urgent need for new ALS
treatment options, particularly those aimed at stopping or slowing
neurodegeneration. We are encouraged by the consistent benefit of
ATH-1105 in these animal models, whether given pre- or post-symptom
onset or in combination with riluzole. These findings underscore
the broad neuroprotective activity of ATH-1105 and support its
ongoing development.”
Poster Presentation (Poster #146): ATH-1105, a
small molecule positive modulator of the hepatocyte growth factor
system, is neuroprotective in a mouse model of ALS when
administered pre- or post-symptom onset, or in combination with
riluzole
ATH-1105 demonstrated neuroprotective properties in several
preclinical models of ALS:
- In vitro, ATH-1105 protected motor neurons from excitotoxicity,
reduced TDP-43 mis-localization, preserved metabolic stability, and
maintained neuromuscular junction integrity.
- In vivo, treatment with ATH-1105 improved motor and nerve
function, mitigated inflammation and neurodegeneration, and reduced
plasma NfL and pTDP-43 accumulation in ALS mice when administered
alone or in combination with riluzole.
NEALS is a closed meeting, and the presentation will be
available on the Scientific Publications &
Presentations page of the company’s website
at www.athira.com.
About ATH-1105ATH-1105 is an orally
administered small molecule designed to positively modulate the
neurotrophic hepatocyte growth factor (HGF) system, which plays a
critical role in nervous system maintenance and repair, including
stimulation of cell survival, increase in neuronal outgrowth and
modulation of neuronal network repair. In preclinical models of
amyotrophic lateral sclerosis (ALS), ATH-1105 has been shown to
significantly increase survival and delay time to first death,
enhance motor and nerve function, reduce motor neuron demyelination
and axon degeneration, and improve biomarkers of neurodegeneration
and inflammation.
About Athira Pharma, Inc.Athira Pharma, Inc.,
headquartered in the Seattle, Washington area, is a late
clinical-stage biopharmaceutical company focused on developing
small molecules to restore neuronal health and slow
neurodegeneration. Athira aims to alter the course of neurological
diseases by advancing its pipeline of therapeutic candidates
targeting the neurotrophic HGF system for Alzheimer’s and
Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic
lateral sclerosis. For more information, visit www.athira.com.
You can also follow Athira on Facebook, LinkedIn, X (formerly known
as Twitter) and Instagram.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding: product
candidates as a potential treatment for Alzheimer’s disease,
Parkinson’s disease, Dementia with Lewy bodies, and other
neurodegenerative diseases, such as amyotrophic lateral sclerosis
and frontotemporal dementia; future development plans; expectations
regarding the potential efficacy and commercial potential of
Athira’s product candidates; and Athira’s ability to advance its
product candidates into later stages of development.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “on
track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,”
“continue,” “suggest,” “potential,” and other similar expressions,
among others. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the data from
preclinical and clinical trials may not support the safety,
efficacy and tolerability of Athira’s product candidates;
development of product candidates may cease or be delayed;
regulatory authorities could object to protocols, amendments and
other submissions; future potential regulatory milestones for
product candidates, including those related to current and planned
clinical studies, may be insufficient to support regulatory
submissions or approval; Athira may not be able to recruit
sufficient patients for its clinical trials; the outcome of legal
proceedings that have been or may in the future be instituted
against Athira, its directors and officers; possible negative
interactions of Athira's product candidates with other treatments;
Athira’s assumptions regarding the sufficiency of its cash, cash
equivalents and investments to fund its planned operations may be
incorrect; adverse conditions in the general domestic and global
economic markets; the impact of competition; regulatory agencies
may be delayed in reviewing, commenting on or approving any of
Athira’s clinical development plans as a result of pandemics or
health epidemics, which could further delay development timelines;
the impact of expanded product development and clinical activities
on operating expenses; the impact of new or changing laws and
regulations; as well as the other risks detailed in Athira’s
filings with the Securities and Exchange Commission from time to
time. These forward-looking statements speak only as of the date
hereof and Athira undertakes no obligation to update
forward-looking statements. Athira may not actually achieve the
plans, intentions, or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on the
forward-looking statements.
Investor & Media ContactJulie RathbunAthira
PharmaJulie.rathbun@athira.com 206-769-9219
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024